

Article

Not peer-reviewed version

The Intertwined Epidemics: Comorbidity of Substance Abuse and Psychiatric Disorders

Richard Murdoch Montgomery *

Posted Date: 2 October 2024

doi: 10.20944/preprints202410.0183.v1

Keywords: Substance Abuse; Psychiatric Disorders; Comorbidity; Dual Diagnosis; Causality; Integrated Treatment; Mental Health



Preprints.org is a free multidiscipline platform providing preprint service that is dedicated to making early versions of research outputs permanently available and citable. Preprints posted at Preprints.org appear in Web of Science, Crossref, Google Scholar, Scilit, Europe PMC.

Copyright: This is an open access article distributed under the Creative Commons Attribution License which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Article

The Intertwined Epidemics: Comorbidity of Substance Abuse and Psychiatric Disorders

Richard Murdoch Montgomery

Universidade de Aveiro, Portugal, mariaantoniavmg@gmail.com

Abstract: Substance abuse and psychiatric disorders are two prevalent and interrelated public health concerns that often coexist, leading to complex clinical scenarios. This comorbidity poses significant challenges in diagnosis, treatment, and understanding the causal relationships between the two conditions. Frequently, one disorder is neglected in favor of the other, and misconceptions abound regarding which condition precipitates the other. This article explores the common comorbidity of substance abuse and psychiatric disorders, delving into the prevalence, diagnostic challenges, treatment implications, and the bidirectional nature of causality. By examining current research and clinical practice, we aim to shed light on the misconceptions and emphasize the need for integrated approaches to effectively address both conditions concurrently.

Keywords: substance abuse; psychiatric disorders; comorbidity; dual diagnosis; causality; integrated treatment; mental health

Section 1. Introduction

The coexistence of substance abuse and psychiatric disorders, often referred to as dual diagnosis or comorbidity, is a pervasive issue that significantly impacts individuals, families, and healthcare systems worldwide. *Epidemiological studies have consistently demonstrated a high prevalence of substance use disorders among individuals with psychiatric disorders and vice versa* (Regier et al., 1990; Kessler et al., 2005). Despite this, there remains a considerable gap in the recognition and treatment of these co-occurring conditions.

The complexity of dual diagnosis arises not only from the overlapping symptoms and diagnostic challenges but also from the misconceptions regarding the causal relationship between substance abuse and psychiatric disorders. Clinicians and researchers often grapple with determining whether substance abuse leads to psychiatric symptoms, psychiatric disorders predispose individuals to substance use, or whether both conditions share common etiological factors (Volkow, 2004; Swendsen et al., 2010).

This review aims to provide a comprehensive analysis of the comorbidity of substance abuse and psychiatric disorders. We will explore the prevalence and patterns of co-occurrence, examine the challenges in diagnosis and treatment, and discuss the misconceptions surrounding causality. By highlighting the importance of integrated treatment approaches, we seek to contribute to a better understanding of dual diagnosis and promote improved outcomes for affected individuals.

Section 1.2 The Prevalence and Patterns of Comorbidity

High Prevalence of Co-Occurrence

Substance abuse and psychiatric disorders frequently co-occur, with numerous studies documenting high rates of comorbidity. The National Comorbidity Survey Replication (NCS-R) found that approximately 50% of individuals with a substance use disorder also had a co-occurring mental disorder (Kessler et al., 2005). Similarly, the Epidemiologic Catchment Area (ECA) study reported that individuals with psychiatric disorders were more than twice as likely to have a substance use disorder compared to those without psychiatric conditions (Regier et al., 1990).

Common Psychiatric Disorders Associated with Substance Abuse

Certain psychiatric disorders are more commonly associated with substance abuse, including:

Mood Disorders: Major depressive disorder and bipolar disorder have high comorbidity rates with substance use disorders. Substance abuse can both exacerbate and be exacerbated by mood symptoms (Conway et al., 2006; Goldstein & Levitt, 2008).

Anxiety Disorders: Disorders such as generalized anxiety disorder, panic disorder, and post-traumatic stress disorder (PTSD) are frequently associated with substance abuse, as individuals may use substances as a form of self-medication to alleviate anxiety symptoms (Jacobsen et al., 2001).

Personality Disorders: Antisocial and borderline personality disorders show a strong association with substance use, often complicating treatment and prognosis (Trull et al., 2000).

Psychotic Disorders: Schizophrenia and other psychotic disorders have significant rates of substance abuse, particularly with substances like cannabis and alcohol, which can affect the course of the illness (Gregg et al., 2007).

Section 2. Discussion

Section 2.1 Patterns of Substance Use

The types of substances abused can vary based on the psychiatric disorder:

Alcohol: Commonly abused across various psychiatric conditions due to its ubiquity and initial anxiolytic effects (Grant & Harford, 1995).

Cannabis: Frequently used by individuals with psychotic disorders, though it may worsen psychotic symptoms (Moore et al., 2007).

Stimulants: Substances like cocaine and methamphetamine are often used by individuals with mood disorders for their euphoric effects (Scott et al., 2007).

Opioids: May be used by individuals with mood and anxiety disorders to relieve emotional pain (Hasin et al., 2005).

Section 2.2 Diagnostic Challenges

Overlapping Symptoms

One of the primary challenges in diagnosing comorbid substance abuse and psychiatric disorders is the *overlap of symptoms*. Substance use can mimic or mask psychiatric symptoms, making it difficult to discern whether symptoms are substance-induced or indicative of a primary psychiatric disorder (Mueser & Kavanagh, 2003).

For example, substance-induced psychosis can present similarly to schizophrenia, and depressive symptoms may result from chronic alcohol use. This overlap necessitates careful assessment and often requires periods of abstinence to clarify the diagnostic picture (Schuckit, 2006).

Underdiagnosis and Misdiagnosis

Underdiagnosis of one condition in the presence of the other is common. Clinicians may focus on the more overt disorder, neglecting the co-occurring condition. *Substance abuse patients may not be screened adequately for psychiatric disorders, and vice versa, leading to ineffective treatment* (Wu & Ringwalt, 2004).

Misdiagnosis can occur when clinicians attribute all symptoms to substance abuse without considering an underlying psychiatric disorder, or when psychiatric symptoms are treated without acknowledging ongoing substance use that may be influencing the clinical presentation (Weaver et al., 2003).

Diagnostic Criteria Limitations

The diagnostic criteria in manuals like the DSM-5 have attempted to address comorbidity, but limitations remain. The criteria may not fully capture the complexity of dual diagnosis, and the artificial separation of disorders can hinder a holistic understanding of the patient (First, 2005).

Section 2.3 Treatment Implications

The Need for Integrated Treatment

Effective treatment of co-occurring substance abuse and psychiatric disorders requires an integrated approach that addresses both conditions simultaneously (Drake et al., 2008). Integrated treatment has been shown to improve engagement, reduce substance use, and alleviate psychiatric symptoms more effectively than sequential or parallel treatment models (Mangrum et al., 2006).

Barriers to Integrated Care

Despite the evidence supporting integrated treatment, several barriers exist:

- Systemic Fragmentation: Mental health and substance abuse services are often provided separately, leading to disjointed care (McGovern & Carroll, 2003).
- Lack of Training: Clinicians may lack the expertise to treat both conditions, resulting in a focus on their area of specialization (Minkoff, 2001a).
- Stigma: Patients may face stigma related to substance abuse or mental illness, discouraging them from seeking comprehensive care (Luoma et al., 2007).

Pharmacological Interventions

Pharmacotherapy can be complicated by comorbidity. Certain medications used to treat psychiatric disorders may interact adversely with substances of abuse or have abuse potential themselves (Brady & Sinha, 2005).

Examples include:

Antidepressants: May be effective but require careful monitoring in patients with alcohol use disorder due to potential liver toxicity (Nunes & Levin, 2004).

Antipsychotics: Necessary for psychotic disorders but may have limited efficacy if substance use continues (Green et al., 2004).

Medications for Substance Abuse: Agents like naltrexone and disulfiram can aid in reducing alcohol use but may not address underlying psychiatric symptoms (Garbutt et al., 2005).

Psychosocial Interventions

Psychosocial treatments are essential components of integrated care:

Cognitive Behavioral Therapy (CBT): Can address both substance use and psychiatric symptoms by modifying maladaptive thought patterns (McHugh et al., 2010).

Motivational Interviewing: Helps enhance motivation to change substance use behaviors and engage in treatment (Hettema et al., 2005).

Support Groups: Dual diagnosis support groups provide peer support and understanding of the challenges associated with comorbidity (Daley, 2006).

Section 2.4 Misconceptions and Causality

The Bidirectional Relationship

A significant misconception in the context of comorbidity is the oversimplified notion that one disorder invariably causes the other, when in reality, the relationship between substance abuse and psychiatric disorders is often bidirectional and complex. Chronic substance abuse can induce psychiatric symptoms due to neurochemical alterations (Koob & Volkow, 2010), while individuals with psychiatric disorders may use substances to self-medicate (Khantzian, 1997). Furthermore, shared genetic, environmental, and neurobiological vulnerabilities may predispose individuals to both conditions (Volkow & Li, 2004). Treatment approaches often fall into the trap of neglecting one disorder over the other, with some programs focusing solely on abstinence while failing to address underlying psychiatric conditions (Timko & Sempel, 2004), or conversely, treating psychiatric symptoms without addressing substance use (Hesse, 2009). Clinicians frequently grapple with the "chicken and egg" dilemma of determining which disorder came first, but an overemphasis on causality may detract from effectively addressing both conditions simultaneously (Cleary et al., 2009). Understanding these complexities and avoiding these common misconceptions is crucial for

developing comprehensive and effective treatment strategies for individuals with comorbid substance abuse and psychiatric disorders.

Section 2.5 The Importance of Comprehensive Assessment

Comprehensive assessment is the cornerstone of effectively identifying and treating comorbid substance abuse and psychiatric disorders. This process should employ standardized screening tools and clinical interviews to evaluate the full spectrum of symptoms, considering the temporal relationship between symptom onset and substance use, understanding substance use patterns, and gathering psychiatric history (Sacks & Ries, 2005). Treatment approaches must be tailored to each individual, taking into account the severity of each disorder, patient motivation, and cultural and social factors that can influence substance use and access to care. To enhance integrated care models, policy and systemic changes are needed to encourage collaboration between mental health and substance abuse services (Minkoff, 2001b). Additionally, providing clinicians with specialized training in dual diagnosis can improve competence and confidence in treating comorbidity (Saunders et al., 2015), while public health campaigns can help reduce the stigma associated with mental illness and substance abuse (Corrigan et al., 2012).

Further research is crucial to advance our understanding and treatment of comorbid disorders. Longitudinal studies are needed to elucidate the causal mechanisms underlying comorbidity, which can inform the development of novel interventions targeting both conditions simultaneously. These may include new pharmacological agents and psychotherapeutic approaches. Moreover, evaluating the efficacy of different integrated treatment models across diverse populations is essential for improving patient outcomes. By addressing these research directions, we can continue to refine our approach to comorbid substance abuse and psychiatric disorders, ultimately leading to more effective and personalized treatment strategies that address the complex interplay between these conditions.

Section 3. Conclusion

The comorbidity of substance abuse and psychiatric disorders represents a significant challenge in mental health care. Misconceptions about causality and the tendency to neglect one disorder over the other hinder effective treatment and recovery. Emphasizing the bidirectional and complex relationship between these conditions is essential.

Integrated treatment approaches that address both substance abuse and psychiatric symptoms concurrently offer the most promising outcomes. Overcoming barriers to integrated care requires systemic changes, increased clinician training, and efforts to reduce stigma.

By advancing our understanding of the intertwined nature of substance abuse and psychiatric disorders and implementing comprehensive, patient-centered care, we can improve the lives of those affected by these overlapping epidemics.

References

1. Brady, K. T., & Sinha, R. (2005). Co-occurring mental and substance use disorders: the neurobiological effects of chronic stress. *The American Journal of Psychiatry*, 162(8), 1483-1493.
2. Cleary, M., Hunt, G. E., & Matheson, S. (2009). Psychosocial treatments for people with co-occurring severe mental illness and substance misuse: systematic review. *Journal of Advanced Nursing*, 65(2), 238-258.
3. Conway, K. P., Compton, W., Stinson, F. S., & Grant, B. F. (2006). Comorbidity between DSM-IV alcohol and drug use disorders and DSM-IV mood and anxiety disorders: results from the National Epidemiologic Survey on Alcohol and Related Conditions. *Drug and Alcohol Dependence*, 80(1), 105-116.
4. Corrigan, P. W., Morris, S. B., Michaels, P. J., Rafacz, J. D., & Rüsch, N. (2012). Challenging the public stigma of mental illness: a meta-analysis of outcome studies. *Psychiatric Services*, 63(10), 963-973.
5. Daley, D. C. (2006). Dual disorders recovery counseling. *Journal of Chemical Dependency Treatment*, 8(2), 5-23.
6. Drake, R. E., O'Neal, E. L., & Wallach, M. A. (2008). A systematic review of psychosocial research on psychosocial interventions for people with co-occurring severe mental and substance use disorders. *Journal of Substance Abuse Treatment*, 34(1), 123-138.
7. First, M. B. (2005). Mutually exclusive versus co-occurring diagnostic categories: The challenge of diagnostic comorbidity. *Psychopathology*, 38(4), 206-210.

8. Garbutt, J. C., West, S. L., Carey, T. S., Lohr, K. N., & Crews, F. T. (1999). Pharmacological treatment of alcohol dependence: a review of the evidence. *JAMA*, 281(14), 1318-1325.
9. Goldstein, B. I., & Levitt, A. J. (2008). The specific burden of comorbid anxiety disorders and of substance use disorders in bipolar I disorder. *Bipolar Disorders*, 10(1p2), 67-78.
10. Grant, B. F., & Harford, T. C. (1995). Comorbidity between DSM-IV alcohol use disorders and major depression: results of a national survey. *Drug and Alcohol Dependence*, 39(3), 197-206.
11. Green, A. I., Zimmet, S. V., Strous, R. D., & Schildkraut, J. J. (1999). Clozapine for comorbid substance use disorder and schizophrenia: do patients with schizophrenia have a reward-deficiency syndrome that can be ameliorated by clozapine? *Harvard Review of Psychiatry*, 6(6), 287-296.
12. Gregg, L., Barrowclough, C., & Haddock, G. (2007). Reasons for increased substance use in psychosis. *Clinical Psychology Review*, 27(4), 494-510.
13. Hasin, D. S., Goodwin, R. D., Stinson, F. S., & Grant, B. F. (2005). Epidemiology of major depressive disorder: results from the National Epidemiologic Survey on Alcoholism and Related Conditions. *Archives of General Psychiatry*, 62(10), 1097-1106.
14. Hesse, M. (2009). Integrated treatment for dual disorders: A critical review. *Current Opinion in Psychiatry*, 22(3), 326-331.
15. Hettema, J. E., Steele, J., & Miller, W. R. (2005). Motivational interviewing. *Annual Review of Clinical Psychology*, 1, 91-111.
16. Jacobsen, L. K., Southwick, S. M., & Kosten, T. R. (2001). Substance use disorders in patients with posttraumatic stress disorder: A review of the literature. *The American Journal of Psychiatry*, 158(8), 1184-1190.
17. Kessler, R. C., Chiu, W. T., Demler, O., & Walters, E. E. (2005). Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. *Archives of General Psychiatry*, 62(6), 617-627.
18. Khantzian, E. J. (1997). The self-medication hypothesis of substance use disorders: A reconsideration and recent applications. *Harvard Review of Psychiatry*, 4(5), 231-244.
19. Koob, G. F., & Volkow, N. D. (2010). Neurocircuitry of addiction. *Neuropsychopharmacology*, 35(1), 217-238.
20. Luoma, J. B., Kohlenberg, B. S., Hayes, S. C., Bunting, K., & Rye, A. K. (2007). Self-stigma in substance abuse: development of a new measure. *Journal of Psychopathology and Behavioral Assessment*, 29(4), 223-234.
21. Mangrum, L. F., Spence, R. T., & Lopez, M. (2006). Integrated versus parallel treatment of co-occurring psychiatric and substance use disorders. *Journal of Substance Abuse Treatment*, 30(1), 79-84.
22. McGovern, M. P., & Carroll, K. M. (2003). Evidence-based practices for substance use disorders. *Psychiatric Clinics*, 26(4), 991-1010.
23. McHugh, R. K., Hearon, B. A., & Otto, M. W. (2010). Cognitive behavioral therapy for substance use disorders. *The Psychiatric Clinics of North America*, 33(3), 511-525.
24. Minkoff, K. (2001a). Developing standards of care for individuals with co-occurring psychiatric and substance use disorders. *Psychiatric Services*, 52(5), 597-599.
25. Minkoff, K. (2001b). Best practices: Developing standards of care for individuals with co-occurring psychiatric and substance use disorders. *Psychiatric Services*, 52(5), 597-599.
26. Moore, T. H., Zammit, S., Lingford-Hughes, A., Barnes, T. R., Jones, P. B., Burke, M., & Lewis, G. (2007). Cannabis use and risk of psychotic or affective mental health outcomes: a systematic review. *The Lancet*, 370(9584), 319-328.
27. Mueser, K. T., & Kavanagh, C. (2003). Cognitive-behavioral therapy for alcohol dependence and concurrent psychotic disorders: description of a program and review of the literature. *Clinical Psychology Review*, 23(7), 973-1006.
28. Nunes, E. V., & Levin, F. R. (2004). Treatment of depression in patients with alcohol or other drug dependence: a meta-analysis. *JAMA*, 291(15), 1887-1896.
29. Regier, D. A., Farmer, M. E., Rae, D. S., Locke, B. Z., Keith, S. J., Judd, L. L., & Goodwin, F. K. (1990). Comorbidity of mental disorders with alcohol and other drug abuse. *JAMA*, 264(19), 2511-2518.
30. Sacks, S., & Ries, R. K. (2005). Substance abuse treatment for persons with co-occurring disorders. *Treatment Improvement Protocol (TIP) Series*, No. 42.
31. Saunders, E. C., Miller, S., Forberger, S., Adams, S., & Lovejoy, T. I. (2015). Evaluation of a training program to improve implementation of dual diagnosis services. *Administration and Policy in Mental Health and Mental Health Services Research*, 42(4), 448-462.
32. Schuckit, M. A. (2006). Comorbidity between substance use disorders and psychiatric conditions. *Addiction*, 101, 76-88.
33. Scott, J. C., Woods, S. P., Matt, G. E., Meyer, R. A., Heaton, R. K., & Atkinson, J. H. (2007). Neurocognitive effects of methamphetamine: A critical review and meta-analysis. *Neuropsychology Review*, 17(3), 275-297.

34. Swendsen, J., Conway, K. P., Degenhardt, L., Glantz, M., Jin, R., Merikangas, K. R., Sampson, N., & Kessler, R. C. (2010). Mental disorders as risk factors for substance use, abuse and dependence: Results from the 10-year follow-up of the National Comorbidity Survey. *Addiction*, 105(6), 1117-1128.
35. Timko, C., & Sempel, J. M. (2004). Short-term outcomes of matching dual diagnosis patients' symptom severity to treatment intensity. *Journal of Substance Abuse Treatment*, 26(3), 209-218.
36. Trull, T. J., Sher, K. J., Minks-Brown, C., Durbin, J., & Burr, R. (2000). Borderline personality disorder and substance use disorders: A review and integration. *Clinical Psychology Review*, 20(2), 235-253.
37. Volkow, N. D. (2004). Scientific research on addiction and its relationship to criminal behavior. National Institute on Drug Abuse.
38. Volkow, N. D., & Li, T. K. (2004). Drug addiction: the neurobiology of behaviour gone awry. *Nature Reviews Neuroscience*, 5(12), 963-970.
39. Weaver, T., Madden, P., Charles, V., Stimson, G., Renton, A., Tyrer, P., Barnes, T., Bench, C., Middleton, H., & Wright, N. (2003). Comorbidity of substance misuse and mental illness in community mental health and substance misuse services. *The British Journal of Psychiatry*, 183(4), 304-313.
40. Wu, L. T., & Ringwalt, C. L. (2004). Use of screening instruments and diagnostic services for substance use disorders in hospitals. *Psychiatric Services*, 55(11), 1396-1402.

Disclaimer/Publisher's Note: The statements, opinions and data contained in all publications are solely those of the individual author(s) and contributor(s) and not of MDPI and/or the editor(s). MDPI and/or the editor(s) disclaim responsibility for any injury to people or property resulting from any ideas, methods, instructions or products referred to in the content.